Alnylam Pharmaceuticals (NASDAQ: ALNY) Q2 2026 Earnings Preview for Thursday July 30 Before Market Open With 8:30 AM ET Conference Call: Wall Street Consensus of $2.05 Earnings Per Share (+540.6% Year-Over-Year) on Revenue of $1.32 Billion (+70.4% Year-Over-Year) Reflects the Continued Ramp of Amvuttra (Vutrisiran) for Both Hereditary Transthyretin Amyloid Polyneuropathy and Cardiomyopathy After the Q1 2026 Amvuttra Revenue of $889.9 Million (+187% YoY); Analyst Focus Includes ALN-6222 Obesity siRNA Phase 1 Program (NCT07624071) and the ALN-2232 Phase 1 Readout Expected in the Second Half of 2026
Alnylam Pharmaceuticals (NASDAQ: ALNY) reports Q2 2026 earnings Thursday July 30, 2026 before market open with an 8:30 AM ET conference call. Wall Street consensus estimates: EPS of $2.05 (+540.6% year-over-year) and revenue of $1.32 billion (+70.4% year-over-year), reflecting the continued commercial ramp of Amvuttra (vutrisiran) across both hereditary transthyretin amyloid polyneuropathy (hATTR-PN) and hereditary transthyretin amyloid cardiomyopathy (hATTR-CM) after the Q1 2026 Amvuttra revenue of $889.9 million (+187% YoY). Analyst focus areas beyond the base-business ramp include: the ALN-6222 first-in-human Phase 1 obesity siRNA program (NCT07624071) that opened enrollment in July 2026 as a randomized double-blind placebo-controlled single-ascending-dose study of an undisclosed-target subcutaneous siRNA in adults with BMI 30-40 kg/m²; the ALN-2232 Phase 1 obesity program (Alnylam's second obesity-track siRNA) with Phase 1 readout expected in the second half of 2026; the Alnylam-PeptiDream peptide-siRNA conjugate extrahepatic delivery platform milestone announced December 2025; and the broader Alnylam 2030 strategy launch positioning beyond the Amvuttra franchise.